Dimri Manali, Satyanarayana Ande
Department of Biochemistry and Molecular Biology, Molecular Oncology & Biomarkers Program, Georgia Cancer Center, Augusta University, Room-CN3144, 1410 Laney Walker Blvd., Augusta, GA 30912, USA.
Cancers (Basel). 2020 Feb 20;12(2):491. doi: 10.3390/cancers12020491.
Hepatocellular carcinoma (HCC) is a complex biological process and is often diagnosed at advanced stages with no effective treatment options. With advances in tumor biology and molecular genetic profiling, several different signaling pathways and molecular mechanisms have been identified as responsible for initiating and promoting HCC. Targeting these critical pathways, which include the receptor tyrosine kinase pathways, the Ras mitogen-activated protein kinase (Ras/Raf/MAPK), the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR), the Wnt/β-catenin signaling pathway, the ubiquitin/proteasome degradation and the hedgehog signaling pathway has led to the identification of novel therapeutics for HCC treatment. In this review, we elaborated on our current understanding of the signaling pathways involved in the development and initiation of HCC and anticipate the potential targets for therapeutic drug development.
肝细胞癌(HCC)是一个复杂的生物学过程,通常在晚期才被诊断出来,且没有有效的治疗选择。随着肿瘤生物学和分子基因谱分析的进展,已确定几种不同的信号通路和分子机制与HCC的发生和发展有关。针对这些关键通路,包括受体酪氨酸激酶通路、Ras丝裂原活化蛋白激酶(Ras/Raf/MAPK)、磷脂酰肌醇3激酶(PI3K)/AKT/雷帕霉素哺乳动物靶点(mTOR)、Wnt/β-连环蛋白信号通路、泛素/蛋白酶体降解和刺猬信号通路,已促成了用于HCC治疗的新型疗法的发现。在本综述中,我们阐述了目前对参与HCC发生和发展的信号通路的理解,并展望了治疗药物开发的潜在靶点。